CEOs and Contract Manufacturers Targeted in Latest Warning Letters
This article was originally published in The Gold Sheet
Executive Summary
FDA sent six of its last nine drug GMP warning letters to contract manufacturing facilities. Most of the letters emphasized corporate accountability, and many went directly to CEOs.
You may also be interested in...
FDA Drug GMP Warning Letters Increase 6%, Focus on Supply Chain and Sterility Assurance in FY 2011
The number of drug GMP warning letters issued by FDA continued to climb in fiscal year 2011, with supply chain and sterility assurance issues dominating the agency’s attention. FDA is requesting a budget increase in FY 2013 to expand its inspectional presence abroad to better meet global supply chain threats, and agency officials are saying that failure to monitor contract manufacturers is a major problem shown in recent warning letters, but that failure to investigate out-of-specification results is still the No. 1 finding.
Another Busy Year of Drug Recalls Led to Shortages of Injectables
Manufacturers recalled more drug products from the U.S. market in 2010 than they had in any year but 2009.
Another Busy Year of Drug Recalls Led to Shortages of Injectables
Manufacturers recalled more drug products from the U.S. market in 2010 than they had in any year but 2009.